Effects of deferoxamine on blood-brain barrier disruption after subarachnoid hemorrhage - Fig 3

Abstract

<p><b>(A</b>) Occludin immunoreactivity and protein levels in cortex after sham or subarachnoid hemorrhage induction with deferoxamine (DFX) treatment or vehicle at day 3, scale bar = 20μm. Values are mean ± SD; n = 3 for each group, #p<0.01, *p<0.05 vs. SAH+vehicle group at day 3. <b>(B)</b> ZO-1 immunoreactivity and protein levels in cortex after sham or subarachnoid hemorrhage induction with deferoxamine (DFX) treatment or vehicle at day 3, scale bar = 20μm. Values are mean ± SD; n = 3 for each group, #p<0.01 vs. SAH+vehicle group at day 3. <b>(C)</b> Claudin-5 immunoreactivity and protein levels in cortex after sham or subarachnoid hemorrhage induction with deferoxamine (DFX) treatment or vehicle at day 3, scale bar = 20μm. Values are mean ± SD; n = 3 for each group, *p<0.05 vs. SAH+vehicle group at day 3.</p